Price: $22.68
· 1 day: -2.74% · 5 days: +7.08% · 1 month: -15.53% · YTD: -35.35%
As of 2026-09-23 20:00 UTC.
52-week range: $21.02 – $42.2 (currently at 8% of the range).
The read
NAMS is in a downtrend, momentum firm. $25 is the level overhead; $21.16 the first support below.
4 of 6 technical checks lean bearish.
Price vs 50-day: below
Price vs 200-day: below
50d vs 200d avg: below
MACD: bullish
RSI momentum: 36
5-day tape: +7.1%
Trend
Downtrend · below 50-day & below 200-day
Momentum
RSI 35.58 · neutral · MACD bullish
Trend strength
ADX 44.7 · strong trend
Location
-15.2% vs 50-day MA
52-week range
-45% from high · +7% from low
Volatility
ATR 1.53 · ~6.7%/day
Key levels
Level
Type
Distance
$25.0 (resistance)
round
10.23%
$25.88 (resistance)
swing zone
14.11%
$26.73 (resistance)
sma 50
17.86%
$21.16 (support)
52w low
-6.7%
$20.0 (support)
round
-11.82%
$15.0 (support)
round
-33.86%
Indicators
RSI (14)
35.58
MACD
-1.3879
ADX (14)
44.7
ATR (14)
1.53
50-day average
$26.73
200-day average
$31.59
Next earnings: 2026-11-04.
Latest NAMS news
NewAmsterdam Pharma Co N.V. — Form 8-K: 8.01 Other Events — NewAmsterdam Pharma Co N.V. filed a Form 8-K with the SEC on September 21, 2026, disclosing an event under Item 8.01 (Other Events). The filing, sourced from SEC EDGAR, does not specify the nature of the event, and no fi (SEC EDGAR, 2026-09-21)
NewAmsterdam Pharma Co N.V. — Quarterly report (10-Q) — NewAmsterdam Pharma Co N.V. filed its SEC Form 10-Q for the second quarter of fiscal year 2026, reporting revenue of $3.7 million, an 81% decline year-over-year. The company posted a net loss of $64.1 million, marking a (SEC EDGAR, 2026-08-05)